DiogenX
Business Services · France · 1-10 Employees
View Company Info for Free
Overview
Headquarters
180 Avenue Du Prado, Marseille, Provence...Website
www.diogenx.comRevenue
<$5 MillionIndustry
About DiogenX
Is DiogenX your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if DiogenX is spiking on competitors!
Check if DiogenX has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at DiogenX
Funding: Get notified immidiatlly once DiogenX has new funding data
Website visits: Recent activity has been detected on your website
DiogenX, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on DiogenX recently announced quarterly report
Product Launch: Get notified when DiogenX launches new products
Click to see if DiogenX had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at DiogenX
Find more new buyers
Company Profile Activity
Activity Insights
DiogenX is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
DiogenX is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about DiogenX.
DiogenX financials insights
Gather financial insights about DiogenX, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Series A
$30.3M
DiogenX Tech Stack
A closer look at the technologies used by DiogenX
DiogenX News & Media
Top Business Services Companies
Frequently Asked Questions Regarding DiogenX
DiogenX is a preclinical stage biotech company committed to a single mission: to discover and develop innovative biologics as new therapeutics options for millions of Diabetic patients around the world. The company's lead program, originating from Dr Patrick Collombat’s laboratory, is based on a new approach targeting beta-cell failure throughout t... Read More